PnuVax

Focused on manufacturing preventative medicine, PnuVax Incorporated has developed high-quality biopharmaceuticals that promote health on a global level, specifically focusing on defeating pneumonia, which stands as the leading cause of mortality among young people worldwide. Fielding a team with more than three decades of pharmaceutical sector experience, PnuVax offers experience in research as well as in commercial production.

Among PnuVax’s milestones has been securing a major foundation grant to enable vaccine clinical development and biomanufacturing expansion. The late 2017 grant brought focus to PnuVax’s patented conjugation platform technology, which offers coverage against several distinct variations, or serotypes, of the pneumococcus bacterium. With PnuVax manufacturing plants centered in Montreal, Canada, the innovative methods in play promise to increase yield at a significantly lower per-dose cost.

At the head of PnuVax is Dr. Donald Gerson, who holds five patents and is widely published in areas such as biochemical engineering, immunology, biophysics, and cell physiology. His accomplishments include guiding the CGMP biosimilars manufacturer Celltrion, Inc., which developed a pioneering biologicals facility in South Korea that achieved US FDA approval.